斯坦丁染料结合物用于选择性向KRAS突变癌细胞
Hye-Ran Moon1,2, Zhenying Cai3, Bo Kyung Cho4
1School of Mechanical Engineering, Purdue University, West Lafayette, Indiana, United States of America.
PloS one
|January 9, 2026
概括
新的他类染料结合物显示选择性吸收和杀死KRAS突变胰腺癌细胞. 这种有针对性的方法为KRAS突变胰腺管腺癌 (PDAC) 提供了一个有希望的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物运输 药物运输 药物运输
背景情况:
- 胰腺管道腺癌 (PDAC) 经常含有KRAS突变 (KRASMUT),限制了治疗选择.
- 类药物对KRAS转化细胞表现出选择性毒性,这表明有针对性治疗的潜力.
研究的目的:
- 合成和评估用于选择性吸收和向KRASMUT细胞的他类染料结合物.
- 在胰腺癌模型中评估这些结合物的治疗潜力.
主要方法:
- 合成西姆瓦斯塔丁-Cy5.5和普拉瓦斯塔丁-Cy5.5联合体.
- 在KRASMUT和KRAS野生型 (KRASWT) 细胞和癌症相关纤维细胞 (CAFs) 中对结合物吸收的评估.
- 在共同培养PDAC模型中评估结合剂介导的细胞杀死.
主要成果:
- 与KRASWT细胞相比,斯坦丁染料合物在KRASMUT细胞中显著增强了吸收.
- 吸收是由巨细胞酶酶介导的,在PTEN缺乏细胞中进一步增强.
- 在共同培养模型中,普拉瓦斯塔丁-Cy5.5可选择性地杀死KRASMUT胰腺癌细胞,而不会影响KRASWT CAF.
结论:
- 斯坦丁染料结合剂有效地选择性向并杀死KRASMUT胰腺癌细胞.
- 这些合物代表了KRASMUT癌症治疗的新,协同方法.
- 这些发现支持开发基于他类药物的合物,用于KRASMUT PDAC的向输送.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.4K
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.6K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
